Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma

NCT00794950 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.

NCT NCT00794950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00794950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Lead sponsor
University of Michigan
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
August 22, 2016
Enrollment
43 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

urinary tract urothelial carcinoma